Loading
Hatem Soliman is a breast oncologist leading immunotherapy and genomic-assay trials, including in triple-negative disease.
Hatem Soliman is Medical Director of the Clinical Trials Office and a breast oncologist at Moffitt Cancer Center. He is known for leading immunotherapy and genomic-assay trials in breast cancer, including in triple-negative disease, and for work validating breast genomic classifiers. His selected paper reports a phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer. He now runs Moffitt's clinical trials office and continues as an investigator in triple-negative and hormone receptor-positive breast cancer studies.
| Title | Journal | Year |
|---|---|---|
| A phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer | Cancer Immunology Research | 2018 |